Breaking News, Financial News

Financial Report: Alexion

Soliris sales up 39% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Alexion 3Q Revenues: $555.1 million (+39%) 3Q Earnings: $177.7 million (+89%) YTD Revenues: $1.6 billion (+48%) YTD Earnings: $503.6 million (+85%) Comments: Soliris sales were $555.1 million in the quarter, up 39%, driven by steady additions of new patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) commencing Soliris treatment. R&D expenses were $100.7 million in the quarter, up 14%....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters